[
  {
    "ts": null,
    "headline": "Pharma sector outlook as Trump's drug tariff deadline looms",
    "summary": "Pharmaceutical stocks are in focus as President Trump's drug tariff deadline looms. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination with Josh Lipton to discuss the impact that pharmaceutical tariffs could have on the sector, Astrazeneca’s (AZN) $50 billion commitment to US investments, and how the industry is navigating pressure from Washington and shifting global demand. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=70ca672e6fd4e363c7c1b4bb9ea9d687b46f09a425e0b23a0b520aada557cd1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753214713,
      "headline": "Pharma sector outlook as Trump's drug tariff deadline looms",
      "id": 136038196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pharmaceutical stocks are in focus as President Trump's drug tariff deadline looms. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination with Josh Lipton to discuss the impact that pharmaceutical tariffs could have on the sector, Astrazeneca’s (AZN) $50 billion commitment to US investments, and how the industry is navigating pressure from Washington and shifting global demand. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=70ca672e6fd4e363c7c1b4bb9ea9d687b46f09a425e0b23a0b520aada557cd1e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors despite daily gains",
    "summary": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=cb55b4dfab27a9a08f60c1554e1eecb39965cd13813c1f3113c6a35ae6e51ae7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753201860,
      "headline": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors despite daily gains",
      "id": 136041278,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=cb55b4dfab27a9a08f60c1554e1eecb39965cd13813c1f3113c6a35ae6e51ae7"
    }
  },
  {
    "ts": null,
    "headline": "LILLY PULITZER LAUNCHES THE VINTAGE VAULT, CELEBRATING OVER SIX DECADES OF ARCHIVED PRINTS",
    "summary": "Lilly Pulitzer, the originator of American Resort Wear, is proud to announce the opening of Lilly's Vintage Vault, a vibrant new chapter in the brand's 65+ year legacy that honors over six decades of colorful design history through the reintroduction of its most beloved archival prints.",
    "url": "https://finnhub.io/api/news?id=f0559dafd1f04621e95813bc69d153570234599db72f728e93fba5e623fd3b2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753200000,
      "headline": "LILLY PULITZER LAUNCHES THE VINTAGE VAULT, CELEBRATING OVER SIX DECADES OF ARCHIVED PRINTS",
      "id": 136033299,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly Pulitzer, the originator of American Resort Wear, is proud to announce the opening of Lilly's Vintage Vault, a vibrant new chapter in the brand's 65+ year legacy that honors over six decades of colorful design history through the reintroduction of its most beloved archival prints.",
      "url": "https://finnhub.io/api/news?id=f0559dafd1f04621e95813bc69d153570234599db72f728e93fba5e623fd3b2c"
    }
  },
  {
    "ts": null,
    "headline": "AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures",
    "summary": "AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.",
    "url": "https://finnhub.io/api/news?id=2e741b154497c11aacd7734185112b38fb2b6547954a7fd022900bb864a4e989",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753198980,
      "headline": "AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures",
      "id": 136033300,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.",
      "url": "https://finnhub.io/api/news?id=2e741b154497c11aacd7734185112b38fb2b6547954a7fd022900bb864a4e989"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=0d27f7e42670b4368c548d76719485fc681a6faf9bfd7d24214ecae10897576a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753191902,
      "headline": "Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term",
      "id": 136033301,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=0d27f7e42670b4368c548d76719485fc681a6faf9bfd7d24214ecae10897576a"
    }
  },
  {
    "ts": null,
    "headline": "15 names that Morgan Stanley’s analysts expect to move meaningfully on earnings",
    "summary": "Investing.com -- Morgan Stanley expects a “normal” earnings beat rate for the second quarter, with S&P 500 EPS growth forecast at 5% year-over-year and sales up 4%.",
    "url": "https://finnhub.io/api/news?id=87d2d84e52c47bbd71b2829e008bb8e643e935610ca4a73cd7df2e711202c3f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753183212,
      "headline": "15 names that Morgan Stanley’s analysts expect to move meaningfully on earnings",
      "id": 136031031,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Morgan Stanley expects a “normal” earnings beat rate for the second quarter, with S&P 500 EPS growth forecast at 5% year-over-year and sales up 4%.",
      "url": "https://finnhub.io/api/news?id=87d2d84e52c47bbd71b2829e008bb8e643e935610ca4a73cd7df2e711202c3f6"
    }
  },
  {
    "ts": null,
    "headline": "Better Growth Buy: Eli Lilly vs. Viking Therapeutics",
    "summary": "Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline.  Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.  Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX) have garnered considerable attention over the past year due to their solid clinical progress.",
    "url": "https://finnhub.io/api/news?id=77c5797b660d03aeacee0e01edebd4b6c7ac8a083f6562dc95a9b2a9f77e5247",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753182900,
      "headline": "Better Growth Buy: Eli Lilly vs. Viking Therapeutics",
      "id": 136031224,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline.  Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.  Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX) have garnered considerable attention over the past year due to their solid clinical progress.",
      "url": "https://finnhub.io/api/news?id=77c5797b660d03aeacee0e01edebd4b6c7ac8a083f6562dc95a9b2a9f77e5247"
    }
  },
  {
    "ts": null,
    "headline": "Should You Invest in the VanEck Pharmaceutical ETF (PPH)?",
    "summary": "Sector ETF report for PPH",
    "url": "https://finnhub.io/api/news?id=22ccc0f2ddbb960f6d5a9f674d0a62aa236ba29ab95245c3d6ce8041a2adab58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753179606,
      "headline": "Should You Invest in the VanEck Pharmaceutical ETF (PPH)?",
      "id": 136031225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Sector ETF report for PPH",
      "url": "https://finnhub.io/api/news?id=22ccc0f2ddbb960f6d5a9f674d0a62aa236ba29ab95245c3d6ce8041a2adab58"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results",
    "summary": "Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials.  Shares of these drugmakers could jump if the data from the studies is positive.  Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials.",
    "url": "https://finnhub.io/api/news?id=481153932dcd0a118d9a0418223142728ca633111da836c0879efeeca1e73c97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753172040,
      "headline": "3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results",
      "id": 136031226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials.  Shares of these drugmakers could jump if the data from the studies is positive.  Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials.",
      "url": "https://finnhub.io/api/news?id=481153932dcd0a118d9a0418223142728ca633111da836c0879efeeca1e73c97"
    }
  },
  {
    "ts": null,
    "headline": "BUZZ Investing: Market Gains Broaden",
    "summary": "BUZZ Investing: Market Gains Broaden",
    "url": "https://finnhub.io/api/news?id=52c74254a48b2c07a9c32ccb5495ad89ef31530f0ede23d780e6e7f0dd79e586",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753164240,
      "headline": "BUZZ Investing: Market Gains Broaden",
      "id": 136030355,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=52c74254a48b2c07a9c32ccb5495ad89ef31530f0ede23d780e6e7f0dd79e586"
    }
  }
]